United States Urea Cycle Disorder Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states urea cycle disorder treatment market size was valued at USD 1.13 billion in 2025 and is estimated to grow from USD 1.18 billion in 2026 to reach USD 1.5 billion by 2031, at a CAGR of 4.92% during the forecast period (2026-2031). This report is Segmented by Treatment Type (Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate/Phenylacetate, Carglumic Acid, Amino-Acid Supplements), Enzyme Deficiency Type (OTC, CPS1, AS, ASL, ARG1, NAGS Deficiencies), and Route of Administration (Oral, Intravenous). Market Forecasts are Provided in Terms of Value (USD).

Global United States Urea Cycle Disorder Treatment Market Trends and Insights

Rising Incidence & Newborn-Screening Expansion

In the U.S., approximately 1 in 35,000 births, equating to about 113 infants annually, are born with a urea-cycle defect. Historically, tandem mass-spectrometry programs only identified distal enzyme blocks. However, with the July 2024 addition of argininosuccinic aciduria and citrullinemia type I to the Recommended Uniform Screening Panel, diagnostic delays for these conditions have been reduced by up to three months. While proximal defects like ornithine transcarbamylase remain undetected by routine panels due to a drop in plasma citrulline levels, this oversight leaves around 300 newborns each year at risk of a hyperammonemic crisis before diagnosis. There's notable state-to-state variability: Texas prioritizes ASA and CIT-I, while Illinois screens all four distal disorders but lacks an algorithm for OTC confirmation. In 2025, the National Urea Cycle Disorders Foundation introduced The Partner Network, which now directs positive screens to a metabolic center within 72 hours, bridging a historical care-coordination gap. Despite early diagnoses, 40% of cases still face mortality, highlighting the urgent need for panel enhancements.

FDA Orphan-Drug Incentives & Recent Approvals

In February 2026, pegzilarginase received accelerated approval, achieving an 80% reduction in arginine levels and demonstrating clear functional benefits. This set a significant benchmark for using biochemical surrogate endpoints. Following this, Ultragenyx’s DTX301 gene therapy and iECURE’s ECUR-506 were both fast-tracked, now benefiting from priority FDA guidance under the Regenerative Medicine Advanced Therapy status. Additionally, Satellite Bio’s SB-101 clinched the Rare Pediatric Disease designation in May 2026, earning a transferable voucher potentially worth up to USD 150 million. While orphan-drug exclusivity provides a buffer against competition for biologics, the swift price erosion of small-molecule nitrogen scavengers, exemplified by glycerol phenylbutyrate post-exclusivity, serves as a cautionary tale. This underscores the importance for gene-therapy sponsors to tether pricing to lasting outcome data rather than fleeting statutory monopolies.

High Therapy Cost & Reimbursement Hurdles

Ravicti, priced at a wholesale pack rate of USD 5,785, results in an annual expenditure exceeding USD 300,000 for adults on standard dosing. This significant cost has led commercial and Medicaid plans to implement blanket prior authorizations. UnitedHealthcare's 2025 policy requires established users to follow the same step-therapy protocol as new patients, necessitating repeated trials with generics and potentially delaying access by up to three months. By late 2025, philanthropic copay assistance programs from organizations like HealthWell and NORD reached their enrollment limits, removing critical financial support for underinsured families. With gene-therapy prices expected to exceed USD 2 million per infusion, payers are likely to impose stricter access controls. To address this, sponsors may need to adopt outcome-based guarantees or staged payment models tied to the durability of ammonia-control outcomes.

Other drivers and restraints analyzed in the detailed report include:

• Adoption of Glycerol Phenylbutyrate Orals
• Patient-Advocacy & Awareness Campaigns
• Scarcity of Metabolic Specialty Centers

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Glycerol phenylbutyrate held a 52.24% share of the U.S. market for Urea Cycle Disorder treatments. However, generics from Endo and Aurobindo have reduced branded list prices by nearly 20%. Following the 2024 Mead Johnson supply shock, the U.S. market for amino-acid supplements and medical formulas is expanding at a 4.62% CAGR, driven by neonatal protocols favoring protein-free calories. While step-therapy rules maintain sodium phenylbutyrate's lead for new starts, adherence challenges often lead patients back to glycerol phenylbutyrate within a year. Meanwhile, Carglumic acid continues to serve a niche but stable group with NAGS deficiency.

Second-order effects are influencing procurement strategies: children’s hospitals are broadening dual-sourcing contracts to mitigate single-supplier risks, and specialty pharmacies are offering adherence analytics as a billable service. Formulation R&D is now focusing on taste-masked microcapsules of sodium phenylbutyrate, aiming to counter glycerol phenylbutyrate’s palatability advantage as price differences diminish.

Complete Report Scope:

• By Treatment Type
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate / Phenylacetate
  • Carglumic Acid
  • Amino-acid Supplements & Specialized Formulas
• By Enzyme Deficiency Type
  • Ornithine Transcarbamylase Deficiency
  • Carbamoyl Phosphate Synthetase 1 Deficiency
  • Argininosuccinate Synthetase Def. / Citrullinemia I
  • Argininosuccinate Lyase Deficiency
  • Arginase 1 Deficiency
  • N-Acetylglutamate Synthase Deficiency
  • Others
• By Route of Administration
  • Oral
  • Intravenous

Geography Analysis

Regional disparities divide a single country's landscape into distinct micro-markets. States like Illinois and Massachusetts, which quickly implemented the 2024 screening update, have achieved a 40% reduction in distal UCD diagnostic delays. In contrast, states that adopted the update later continue to experience historical lag times. Medicaid formularies further complicate this landscape: fourteen states designate glycerol phenylbutyrate as the preferred agent for patients on sodium restrictions, while twenty-three states require two documented failures of sodium phenylbutyrate before approval. These regulations influence dispensing channels, with southern states demonstrating a higher ratio of generics to branded medications compared to New England.

Workforce maldistribution intensifies access inequities. While academic centers in Philadelphia, Boston, and Houston serve as hubs for tertiary care, vast rural regions from the Dakotas to the Mountain West lack access to biochemical geneticists. Although telehealth coverage parity laws enacted in California and New York in 2025 improved follow-up adherence, they did not resolve critical transport challenges. In Texas, mobile ECMO and rapid-transfer networks have successfully reduced door-to-dialysis intervals by two hours, and this operational model is now being evaluated in five other states with Medicaid waivers.

Supply-chain disruptions create periodic regional shortages. A 2024 fire at Mead Johnson’s Indiana plant disrupted formula availability across the Midwest, prompting five hospital systems to source amino-acid mixes from European suppliers under FDA enforcement discretion. Gulf Coast compounding facilities, which are vulnerable to hurricanes, are proactively planning similar contingency measures for specialized excipients like phenylacetic acid.

List of Companies Covered in this Report:

• Abbott Laboratories
• Aeglea BioTherapeutics Inc.
• Amicus Therapeutics Inc.
• Arcturus Therapeutics Holdings Inc.
• Bausch Health
• Biomarin Pharmaceutical
• Danone
• Erytech Pharma
• Eurocept Pharmaceuticals / Lucane Pharma SA
• Horizon Therapeutics
• Immedica Pharma AB
• Mead Johnson & Company
• Nestle
• Orpharma
• PTC Therapeutics
• Recordati Rare Diseases Inc.
• Relief Therapeutics Holding AG
• Sana Biotechnology Inc.
• Selecta Biosciences Inc.
• Sobi AB
• Synlogic
• Ultragenyx Pharmaceutical Inc.
• Zevra Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support